NCT02121509View on ClinicalTrials.gov

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Healthy
Interventions
DRUG

Linagliptin

1 x Linagliptin tablet

DRUG

Linagliptin/Metformin ER FDC

2 x Linagliptin/Metformin ER FDC tablet

DRUG

Metformin ER

3 x Metformin ER tablets

Trial Locations (1)

Unknown

1288.10.1 Boehringer Ingelheim Investigational Site, Ingelheim

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY